Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 14/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | TEC | P42680 | 1/20 | 0.39 |
| ▸ | BMX | P51813 | 1/20 | 0.39 |
| ▸ | CD69 | Q07108 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 1/20 | 0.39 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.39 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.39 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10094186 | 0.91 | IRAK4 (0.43) | BTKIRAK4SYK | |
| SCHEMBL10094255 | 0.81 | IRAK4 (0.41) | BTKIRAK4 | |
| SCHEMBL10094252 | 0.80 | IRAK4 (0.43) | IRAK4SYK | |
| SCHEMBL12036733 | 0.80 | IRAK4 (0.61) | IRAK4 | |
| SCHEMBL10094144 | 0.79 | IRAK4 (0.37) | BTKIRAK4SYK | |
| SCHEMBL10094285 | 0.79 | PIK3CA (0.40) | KCNH2SYK | |
| SCHEMBL10094152 | 0.79 | TYRO3 (0.37) | IRAK4SYK | |
| SCHEMBL10094048 | 0.78 | ACHE (0.36) | BTKIRAK4SYK | |
| SCHEMBL12058044 | 0.77 | IRAK4 (0.37) | BTKIRAK4SYK | |
| SCHEMBL10094250 | 0.77 | IRAK4 (0.38) | BTKIRAK4SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110318305-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME LLC | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110318305-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | PNP, XDH, PNPO | BTK 632/4885KCNH2 2904/4885TNK2 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.